Global licensing Santhera holds exclusive worldwide license for AGAMREE (vamorolone) with approvals in multiple major markets and co-licensing arrangements for North America and China; this presents opportunities to coordinate cross-border distribution partnerships and leverage local regulatory insights to accelerate market access.

Expansion opportunities Recent news highlights broadened distribution in Central Asia and the Caucasus via BioMedica partnership, signaling an active strategy to extend access in additional geographies; sales teams should identify regional payor dynamics and tiered market entry plans to replicate growth.

Clinical stage leverage AGAMREE is positioned as a dissociative steroid with potential use in Duchenne muscular dystrophy; as a late-stage asset with FDA and EC approvals, there is room to pursue additional label enhancements, combination therapies, or payer value dossiers to expand indications and reimbursement.

Leadership transitions Upcoming CEO and Chief Commercial Officer appointments, along with leadership succession, indicate a pivotal phase for commercial strategy; engage early with the new leadership to align on product messaging, market access plans, and key account priorities.

Financial runway Strong funding level and recent $40M investment from Nxera Pharma provide liquidity to support geographic expansion, pre-launch or launch activities, and strategic partnerships; sales initiatives can be timed to capitalize on near-term financing to scale outreach and market development.